HLS Therapeutics (HLS) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
14 May, 2026Opening remarks and agenda
Meeting opened with a welcome and instructions for virtual participation, including Q&A and voting procedures.
Forward-looking statements disclaimer was read, highlighting risks and uncertainties.
Agenda included presentation of financial statements, election of directors, and reappointment of auditor.
Board and executive committee updates
Introduction of attending officers and nominees for director positions.
Eight nominees for director positions were named and confirmed as present.
Shareholder proposals
No additional nominations for directors were accepted due to advance notice provisions.
Partial view of Summaries dataset, powered by Quartr API
Latest events from HLS Therapeutics
- Q1 2026 saw revenue and cash growth, NILEMDO's strong launch, and reaffirmed 2026 guidance.HLS
Q1 202615 May 2026 - All directors were elected and the auditor reappointed, with all motions passing by shareholder vote.HLSAGM 202415 May 2026
- EBITDA up 18%, cash flow doubled, Vascepa gains, NILEMDO launch, and net debt reduced.HLSQ4 202530 Apr 2026
- Strong financials and new cardiovascular launches position for accelerated growth post-2026.HLSCorporate presentation23 Apr 2026
- Canadian Vascepa sales rose 30% as costs fell and positive EBITDA is expected in Q4.HLSQ3 202423 Apr 2026
- Core product sales rose 9% and OpEx fell 13%, with $14M debt repaid from royalty sale.HLSQ2 202423 Apr 2026
- Q2 revenue hit $14.2M, EBITDA up 21%, and new cardiovascular launches planned for 2026.HLSQ2 202523 Apr 2026
- Core product growth, cost cuts, and debt reduction set up for 17–23% EBITDA growth in 2025.HLSQ4 202423 Apr 2026
- Q1 2025 delivered strong growth, margin gains, and portfolio expansion with new cardiovascular assets.HLSQ1 202523 Apr 2026